Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 9/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.35 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132 | 1.00 | — | — | |
| Hydroxyl Radical SCHEMBL2733157 | 1.00 | — | — | |
| SCHEMBL2364171 | 0.96 | TSHR (0.46) | TSHRLMNATHRBALDH1A1TDP1 | |
| SCHEMBL20636758 | 0.96 | — | — | |
| SCHEMBL4624152 | 0.96 | — | — | |
| SCHEMBL23451643 | 0.96 | — | — | |
| SCHEMBL12500497 | 0.96 | — | — | |
| SCHEMBL2541301 | 0.96 | — | — | |
| SCHEMBL23045803 | 0.96 | — | — | |
| SCHEMBL11025508 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605271-B2 | Superhigh purity ionic liquid | DAI-ICHI KOGYO SEIYAKU CO., LTD (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20060223995-A1 | Superhigh purity ionic liquid | DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) | 2006-10-05 | — | — | US | disclosed |
| EP-1707265-A1 | Superhigh purity ionic liquid | DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-20030195183-A1 | Method for correcting immune system of live body | ZHILOV VALERII KHAZHUMURATOVIC (RU) | 2003-10-16 | — | — | US | disclosed |
| EP-1315497-A2 | AMINO DERIVATIVES OF 2,3-DIHYDROPHTALAZINE-1,4-DIONE AS IMMUNOCORRECTING AGENTS | Medinkor ZMM AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002009681-A2 | A METHOD FOR CORRECTING THE IMMUNE SYSTEM OF LIVE BODY | MEDINKOR ZMM AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| US-6120978-A | SURFACTANTS AND PHOTORESISTS DEVELOPERS | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0310321-B1 | Immunomodulatory azaspiranes | SMITHKLINE BEECHAM CORP (US) | 1994-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195183-A1 | Method for correcting immune system of live body | IL15, IL5, IL2 | TSHR 2837/4885LMNA 4398/4885THRB 4188/4885 |
| US-20060223995-A1 | Superhigh purity ionic liquid | SLC7A5, SLC7A1, SLC43A1 | TSHR 1119/4885LMNA 2206/4885THRB 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.